TABLE 1

Intraportal cotransplant of allogeneic DBMCs and islets

Group 1 ID no.MHC class II matchIEQ/kgDays off insulinaDecrease in functionbDays C-peptide positive/POD necropsyDose DBMCsc/kg × 109Dose CD34/kg × 106POD chimerismPeak level (%) of chimerism
58 YMM8,000025326/3480.64107NDND
93-343MM9,72492545/450.4862.21, 5∼2
105-111MM11,598122146/610.4371.540.37
  • Animals received induction treatment with four doses of 10 mg/kg thymoglobulin given in the week prior to transplant and four doses of 50 mg/m2 total of fludarabine. IM rapamycin was initiated 1–5 days prior to intraportal islet/DBMC transplant on POD 0, with a goal of achieving trough levels of 15–20 ng/ml. DBMCs were debulked with a CD11b bead-based method. Chimerism was measured using 6 class II based primer and probe sets for donor DNA; the lower limit of detection ranged from 0.03 to 0.1%, depending on the primer probe set.

  • aNot necessarily consecutive to islet transplant.

  • bOn the basis of blood glucose levels, insulin requirement, and/or C-peptide.

  • cTotal DBMC dose; DBMCs were given intraportally on POD 0 and intravenously on PODs 5 and 11. ND, not determined; MM, recipient and donor are MHC class II mismatched.